<DOC>
	<DOCNO>NCT01551173</DOCNO>
	<brief_summary>This study demonstrate therapeutic comparability Fluvastatin sodium Extended Release Tablets 80 mg QD Fluvastatin sodium Immediate Release Capsules 40 mg BID LDL-C lower baseline week 12 ( endpoint ) patient primary hypercholesterolemia mixed dyslipidemia moderate high CV risk achieve lipid goal treat Fluvastatin sodium Immediate Release Capsules 40 mg QD .</brief_summary>
	<brief_title>Efficacy Safety Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily Chinese Patients With Primary Hypercholesterolemia Mixed Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>Patients primary hypercholesterolemia mixed dyslipidemia moderate high CV risk accord Chinese Dyslipidemia Guideline ( 2007 ) . Not achieve lipid treatment goal despite follow cholesterol restrictive diet and/or lipid lower monotherapy improperly prior Visit 1 ( inclusion 6week openlabel study phase ) . Not achieve lipid treatment goal stable dose Fluvastatin sodium Immediate Release Capsule 40 mg QD 6 week openlabel study phase ( inclusion 12week doubleblind study phase ) . Patients know hypersensitivity fluvastatin excipients . Dyslipidemia secondary cause . Known muscle disease history muscle disease and/or serum CPK level great 2 x upper limit normal ( ULN ) . A history evidence Acute Myocardial infarction ( AMI ) , unstable angina ( UA ) Coronary artery bypass surgery Percutaneous Coronary Intervention ( PCI ) within previous 8 week . Active liver disease and/or serum transaminase level ( ALT , AST ) great 1.5 x ULN . Patients proper lipid lower monotherapy ( define least 12 week continuous monotherapy recommend dose administration label ) within previous 3 month prior visit 1 . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Dyslipidemias</keyword>
	<keyword>Fluvastatin sodium</keyword>
	<keyword>Chinese</keyword>
</DOC>